Compare Super Group (SGHC) Limited Ordinary Shares (SGHC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Super Group (SGHC) Limited Ordinary Shares vs Spyre Therapeutics Inc. Common Stock — how do they compare? Super Group (SGHC) Limited Ordinary Shares trades at $11.1 (market cap $5.65B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Super Group (SGHC) Limited Ordinary Shares pays a 1.8% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Super Group (SGHC) Limited Ordinary Shares for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SGHC | SYRE | |
|---|---|---|
Market Cap | $5.65B | $7.35B |
Volume | 1,790,497 | 1,624,631 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.59 | $108.92 |
52-Week Low | $8.52 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $5.19B | $6.35B |
Dividend Yield | 1.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGHC trades at $11.19, down 0.27% with a bearish technical signal despite strong fundamentals. The company shows robust profitability with 53.31% gross margins and 48.9% ROE, while revenue grew to $2.23B in 2025. Recent earnings missed expectations but analyst consensus remains unanimously bullish with 8 buy ratings. Technical indicators show selling pressure with moving averages signaling bearish momentum.
SGHC presents a compelling value opportunity with attractive valuation multiples (P/E 15.55, EV/EBITDA 8.43) and strong cash flow generation. However, recent earnings misses and bearish technical signals create near-term headwinds. The stock's outlook depends on Q3 earnings delivery and sustained sports betting momentum amid competitive pressures.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Super Group (SGHC) Limited Ordinary Shares
Super Group (SGHC) Limited is a holding company for online sports betting and gaming businesses, operating the Betway sports betting brand and the Spin multi-brand online casino portfolio across markets in Europe, the Americas, and Africa.
Read more on SGHC →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
